Contrasting Jaguar Animal Health (NASDAQ:JAGX) & vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics (NASDAQ:VTVT) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Risk and Volatility

vTv Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500.

Earnings and Valuation

This table compares vTv Therapeutics and Jaguar Animal Health”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02 million	102.38	-$26.97 million	($1.06)	-25.00
Jaguar Animal Health	$27.79 million	0.03	-$53.43 million	($3,731.33)	-0.00

vTv Therapeutics has higher earnings, but lower revenue than Jaguar Animal Health. vTv Therapeutics is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares vTv Therapeutics and Jaguar Animal Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Jaguar Animal Health	-187.88%	N/A	-131.45%

Institutional & Insider Ownership

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Jaguar Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for vTv Therapeutics and Jaguar Animal Health, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1	1	6	1	2.78
Jaguar Animal Health	1	0	0	0	1.00

vTv Therapeutics presently has a consensus price target of $55.83, indicating a potential upside of 110.65%. Given vTv Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe vTv Therapeutics is more favorable than Jaguar Animal Health.

Summary

vTv Therapeutics beats Jaguar Animal Health on 12 of the 15 factors compared between the two stocks.

About vTv Therapeutics

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

About Jaguar Animal Health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.